ECSP11011365A - Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh - Google Patents
Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodhInfo
- Publication number
- ECSP11011365A ECSP11011365A EC2011011365A ECSP11011365A ECSP11011365A EC SP11011365 A ECSP11011365 A EC SP11011365A EC 2011011365 A EC2011011365 A EC 2011011365A EC SP11011365 A ECSP11011365 A EC SP11011365A EC SP11011365 A ECSP11011365 A EC SP11011365A
- Authority
- EC
- Ecuador
- Prior art keywords
- groups
- addition salts
- acid derivatives
- carboxyll
- aminas
- Prior art date
Links
- KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical class NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 title 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 title 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a nuevas sales de adición cristalinas, farmacéuticamente aceptables e hidrosolubles de (i) una amina que contiene uno o más grupos hidroxilo y/o carboxílicos con (ii) derivados de ácido aminonicotínico de fórmula donde Ra, Rb, Rc y Rd independientemente representan grupos seleccionados de átomos de hidrógeno, átomos de halógeno, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halógeno y grupos hidroxi, y grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halógeno y grupos hidroxi, y sus solvatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382031A EP2228367A1 (en) | 2009-03-13 | 2009-03-13 | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011365A true ECSP11011365A (es) | 2011-10-31 |
Family
ID=40677683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011365A ECSP11011365A (es) | 2009-03-13 | 2011-09-30 | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20120014918A1 (es) |
| EP (2) | EP2228367A1 (es) |
| JP (1) | JP5674685B2 (es) |
| KR (1) | KR101674699B1 (es) |
| CN (1) | CN102348689B (es) |
| AR (1) | AR075738A1 (es) |
| AU (1) | AU2010223528B2 (es) |
| BR (1) | BRPI1006766B8 (es) |
| CA (1) | CA2754804C (es) |
| CL (1) | CL2011002216A1 (es) |
| CO (1) | CO6420337A2 (es) |
| CY (1) | CY1114418T1 (es) |
| DK (1) | DK2406225T3 (es) |
| EA (1) | EA022350B1 (es) |
| EC (1) | ECSP11011365A (es) |
| ES (1) | ES2428746T3 (es) |
| HR (1) | HRP20130851T1 (es) |
| IL (1) | IL214519A (es) |
| ME (1) | ME01564B (es) |
| MX (1) | MX2011009146A (es) |
| MY (1) | MY155140A (es) |
| NZ (1) | NZ594493A (es) |
| PE (1) | PE20120171A1 (es) |
| PL (1) | PL2406225T3 (es) |
| PT (1) | PT2406225E (es) |
| RS (1) | RS52949B (es) |
| SG (1) | SG173823A1 (es) |
| SI (1) | SI2406225T1 (es) |
| SM (1) | SMT201300104B (es) |
| TW (1) | TWI428127B (es) |
| UA (1) | UA105786C2 (es) |
| UY (1) | UY32467A (es) |
| WO (1) | WO2010102826A1 (es) |
| ZA (1) | ZA201105744B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) * | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| EP2444088A1 (en) * | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Amino derivatives for the treatment of proliferative skin disorders |
| EP2594271A1 (en) * | 2011-11-21 | 2013-05-22 | Almirall, S.A. | 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis. |
| KR101251851B1 (ko) | 2011-11-30 | 2013-04-10 | 현대자동차주식회사 | Ｉｓｇ 시스템 및 이의 제어방법 |
| TW201350467A (zh) * | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| US20160051679A1 (en) * | 2013-04-12 | 2016-02-25 | Actavis Group Ptc Ehf. | Pemetrexed Formulation |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| WO2018157842A1 (zh) * | 2017-03-02 | 2018-09-07 | 中国科学院上海药物研究所 | 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途 |
| IL270066B2 (en) | 2017-04-24 | 2023-10-01 | Aurigene Oncology Ltd | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| KR20210090625A (ko) | 2018-10-09 | 2021-07-20 | 아슬란 파마슈티컬스 피티이 엘티디 | 바를리티닙의 말론산 염 |
| CR20210394A (es) * | 2018-12-21 | 2021-12-13 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo |
| CN116940359A (zh) * | 2020-10-15 | 2023-10-24 | 亚狮康私人有限公司 | 用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病 |
| EP4228640A1 (en) * | 2020-10-15 | 2023-08-23 | ASLAN Pharmaceuticals Pte Ltd | Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
| WO2025227007A1 (en) * | 2024-04-26 | 2025-10-30 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3839344A (en) * | 1973-03-28 | 1974-10-01 | Schering Corp | N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid |
| GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
| AP2002002387A0 (en) * | 1999-06-10 | 2002-03-31 | Warner Lambert Co | Method of inhibiting amyloid aggregation and imaging amyloid deposits. |
| DE60226855D1 (de) | 2001-04-05 | 2008-07-10 | Aventis Pharma Inc | Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose |
| WO2003006424A1 (en) * | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| JP2004099586A (ja) * | 2002-05-21 | 2004-04-02 | Sumitomo Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害剤 |
| WO2004056747A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| US7071355B2 (en) | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| MXPA06013435A (es) | 2004-05-21 | 2007-03-23 | Uab Research Foundation | Composiciones y metodos referentes a inhibidores de sintesis de pirimidina. |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2006044741A1 (en) | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| JP2007015952A (ja) * | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| ES2303758B1 (es) | 2006-02-20 | 2009-08-13 | Laboratorios Almirall S.A. | Nuevos derivados de piridin-3-amina. |
| ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
-
2009
- 2009-03-13 EP EP09382031A patent/EP2228367A1/en not_active Withdrawn
-
2010
- 2010-02-24 UY UY0001032467A patent/UY32467A/es active IP Right Grant
- 2010-03-08 TW TW099106617A patent/TWI428127B/zh active
- 2010-03-11 ES ES10708932T patent/ES2428746T3/es active Active
- 2010-03-11 KR KR1020117021314A patent/KR101674699B1/ko active Active
- 2010-03-11 US US13/256,349 patent/US20120014918A1/en not_active Abandoned
- 2010-03-11 PT PT107089328T patent/PT2406225E/pt unknown
- 2010-03-11 PL PL10708932T patent/PL2406225T3/pl unknown
- 2010-03-11 PE PE2011001599A patent/PE20120171A1/es active IP Right Grant
- 2010-03-11 SG SG2011060811A patent/SG173823A1/en unknown
- 2010-03-11 RS RS20130394A patent/RS52949B/sr unknown
- 2010-03-11 AU AU2010223528A patent/AU2010223528B2/en active Active
- 2010-03-11 EA EA201101297A patent/EA022350B1/ru unknown
- 2010-03-11 SI SI201030344T patent/SI2406225T1/sl unknown
- 2010-03-11 HR HRP20130851AT patent/HRP20130851T1/hr unknown
- 2010-03-11 NZ NZ594493A patent/NZ594493A/xx unknown
- 2010-03-11 JP JP2011553360A patent/JP5674685B2/ja active Active
- 2010-03-11 WO PCT/EP2010/001550 patent/WO2010102826A1/en not_active Ceased
- 2010-03-11 ME MEP-2013-106A patent/ME01564B/me unknown
- 2010-03-11 EP EP10708932.8A patent/EP2406225B1/en active Active
- 2010-03-11 UA UAA201111802A patent/UA105786C2/uk unknown
- 2010-03-11 DK DK10708932.8T patent/DK2406225T3/da active
- 2010-03-11 CA CA2754804A patent/CA2754804C/en active Active
- 2010-03-11 MX MX2011009146A patent/MX2011009146A/es active IP Right Grant
- 2010-03-11 CN CN201080011530.6A patent/CN102348689B/zh active Active
- 2010-03-11 BR BRPI1006766A patent/BRPI1006766B8/pt active IP Right Grant
- 2010-03-11 AR ARP100100741A patent/AR075738A1/es not_active Application Discontinuation
- 2010-03-11 MY MYPI2011004300A patent/MY155140A/en unknown
-
2011
- 2011-08-04 ZA ZA2011/05744A patent/ZA201105744B/en unknown
- 2011-08-08 IL IL214519A patent/IL214519A/en active IP Right Grant
- 2011-09-01 CO CO11112338A patent/CO6420337A2/es not_active Application Discontinuation
- 2011-09-08 CL CL2011002216A patent/CL2011002216A1/es unknown
- 2011-09-30 EC EC2011011365A patent/ECSP11011365A/es unknown
-
2013
- 2013-09-18 CY CY20131100818T patent/CY1114418T1/el unknown
- 2013-09-23 SM SM201300104T patent/SMT201300104B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6420337A2 (es) | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh | |
| CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
| CO6321276A2 (es) | Derivados de tiazol usados como inhibidores de pi3- cinasa | |
| CR20140464A (es) | Compuestos de heterociclilo | |
| IN2014CN00473A (es) | ||
| ECSP11010830A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| CR10784A (es) | Nuevos derivados de aminopirimidina como inhibidores de plki | |
| CR20120053A (es) | Compuestos y metodos inhibidores de jak de pirazolopirimidina | |
| MX2012003982A (es) | Pirrolidinas n-substituidas. | |
| AU2011209274A8 (en) | Substituted naphthyridines and their use as Syk kinase inhibitors | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| AR079250A1 (es) | Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis. | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| MX353190B (es) | Derivados de isoquinolina y naftiridina. | |
| DK2197860T3 (da) | Nye forbindelser som adenosin-A1-receptorantagonister | |
| MX2012006696A (es) | Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina. | |
| EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
| CO6501157A2 (es) | Sales de adición de trometamina con derivados de ácido azabifenilaminobenzoico como inhibidores de dhodh | |
| UY32246A (es) | Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica | |
| MX342960B (es) | Derivados de cromeno. | |
| AR077429A1 (es) | Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos | |
| AR072202A1 (es) | 7-sulfanilmetil-, 7-sulfinilmetil-, y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
| BR112013031791A2 (pt) | derivados de ftalazinona-pirrolopirimidinacarboxamida |